


PRODUCT INFORMATION



CC-122

Item No. 26257

CAS Registry No.: 1015474-32-4
Formal Name: 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-2,6-piperidinedione
Synonym: Avadomide
MF: C₁₄H₁₄N₄O₃
FW: 286.3
Purity: ≥98%
UV/Vis.: λ_{max}: 239, 358 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CC-122 is supplied as a crystalline solid. A stock solution may be made by dissolving the CC-122 in the solvent of choice, which should be purged with an inert gas. CC-122 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of CC-122 in these solvents is approximately 30 mg/ml.

CC-122 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CC-122 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. CC-122 has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

CC-122 is a pleiotropic pathway modifier with anticancer activity.¹ It binds to cereblon, a substrate receptor protein of the Cullin 4 RING E3 ubiquitin ligase complex, in U266 multiple myeloma cell extracts and induces recruitment and degradation of the cereblon substrates Aiolos and Ikaros in TMD8, OCI-LY10, and Karpas 422 diffuse large B cell lymphoma (DLBCL) cells when used at concentrations of 0.1, 1, and 10 μM. CC-122 (0.1-10,000 nM) decreases proliferation and induces apoptosis in activated B cell (ABC) and germinal center B cell (GCB) DLBCL cell lines. It also stimulates IL-2 production in mouse primary T cells. CC-122 (30 mg/kg) decreases tumor levels of Aiolos and Ikaros and reduces tumor growth in OCI-LY10 ABC DLBCL and WSU-DLCL2 GCB DLBCL mouse xenograft models.

Reference

1. Hagner, P.R., Man, H.-W., Fontanillo, C., *et al.* CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. *Blood* **126**(6), 779-789 (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/23/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM